(Market Cap peer comparison.)
Traditional medicine may soon see itself transformed by the $100 billion market opportunity that psychedelics can provide.
Analysts at Eight Capital were quoted by Business Insider called this the “early innings” for this incredibly large addressable market.
Clinical trials from major institutions have found that these drugs have the potential to effectively treat a range of mental and other health related issues, such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, anxiety, and many others.
A specialty life sciences Company focused on the research and development of therapeutics for medical needs and rare disorders,
Revive Therapeutics Ltd. (CSE: RVV, Forum) provided the public with an update in mid-November 2020 on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison.
RVV had completed an oral thin-film strip product with psilocybin, following several months of prototyping on a wide range of dosage forms, ranging between 1 mg and 20 mg and demonstrating its versatility through physio-chemical characterization (e.g. tensile strength of films) of bio comparable tannin-chitosan composite materials, dissolution and disintegration testing, and rate of psilocybin release from composites.
In
a recent news release for investors, the Company’s Chief Executive Officer, Michael Frank noted that by achieving this development milestone, its orally dissolvable thin film strip for psilocybin, can be used in human clinical studies conducted by the US Food and Drug Administration (FDA), as well as a unique product for medical use in states where psilocybin therapy use is permitted, such as Oregon following the passage of Measure 109.
“There is a significant market opportunity for our unique oral thin film strip technology for not only delivering psilocybin but also delivering numerous psychedelic-based medicines to treat various diseases and disorders that would benefit from such a delivery method. Also, we are in a position to begin partnering with life sciences companies seeking to add unique offerings in their psychedelic-based product pipeline and with companies operating in the US where psilocybin therapy use is legal.”
Psilocybin Oral Thin-film Product:
For the better part of the year, Revive has been working with the Reed Research Group out of the University of Wisconsin-Madison to develop its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity. The Company has finalized the prototypes and is preparing to scale for manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines.
Under this sponsored research partnership, the Company has found a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the ease and convenience for patients to administer without the need of water, chewing or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options.
Revive’s Drug Delivery Technology:
Aiming to deliver both synthetic and natural extract of psilocybin in a potential number of ways, this drug delivery technology can be orally dissolvable thin films, topical gels, creams, or ointments, oral or transdermal patches, oral dosages, and foams.
Boasting a natural, non-toxic, biodegradable and biocompatible composite this delivery technology combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.
Investment summary:
Having expanded its cannabinoid delivery system to psychedelics, the breath strip product being rolled out by Revive Therapeutics is more versatile than many would believe, but they can take on a wide range of forms from hydra gels, wafers, oral foams, and patches. The Company has issued three patents, more info can be found
here.
Currently technical and scientific data is being processed and finalized. The medical world is on the verge of a major shift in treatment for mental health, while research and development teams have found that such treatments have “positive long-term mental health consequences, rather than daily neurochemical corrections in brain dysfunctions,” meaning they may help treat conditions better than pharmaceuticals.
As we learn more about the many benefits of such treatments, Revive Therapeutics is proving to be one of the top companies to keep an eye on as it processes and finalizes its own technical and scientific data,
To find out more about the Company, visit
revivethera.com.
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.